

## **Announcement Summary**

## Name of entity

MAYNE PHARMA GROUP LIMITED

#### **Announcement type**

Update announcement

# Type of update

Final buy-back notification

#### Date of this announcement

2/8/2022

#### Reason for update

Final buy-back notification

## ASX Security code and description of the class of +securities the subject of the buy-back

MYX: ORDINARY FULLY PAID

## The type of buy-back is:

#### Total number of +securities bought back

25,025,249

# Total consideration paid or payable for the securities

0.00000

Refer to next page for full details of the announcement

## Part 1 - Entity and announcement details

## 1.1 Name of entity

MAYNE PHARMA GROUP LIMITED

We (the entity named above) provide the following information about our buy-back.

# 1.2 Registration number type

Registration number

ABN

76115832963

#### 1.3 ASX issuer code

MYX

## 1.4 The announcement is

☑ Update/amendment to previous announcement

#### 1.4a Type of update

Final buy-back notification

## 1.4b Reason for update

Final buy-back notification

## 1.4c Date of initial notification of buy-back

1/7/2022

## 1.4d Date of previous announcement to this update

1/7/2022

## 1.5 Date of this announcement

2/8/2022

## 1.6 ASX Security code and description of the class of +securities the subject of the buy-back

MYX: ORDINARY FULLY PAID

# Part 2 - Type of buy-back

2.1 The type of buy-back is: 
☑ Employee share scheme buy-back

Part 3 -	Buy-back	details
----------	----------	---------

Part 3A - Details of +securities, price and reason

3A.1 Total number of +securities on issue in the class of +securities to be bought back

1,764,840,757

3A.2 Total number of +securities proposed to be bought back

25,025,249

3A.9 Are the +securities being bought back for a cash consideration? 

☑ No

#### 3A.9b Please describe the consideration being provided to buy back the +securities

Extinguishment of employee share loans totalling \$22,252,618 originally advanced by the Company to the employees concerned for the purchase of the loan scheme shares being cancelled. No cash is payable by the Company for the buy back.


Part 3B - Buy-back restrictions and conditions

3B.1 Does the buy-back require security holder approval?

☑ No

3B.3 Are there any other conditions that need to be satisfied before the buy-back offer becomes unconditional? 

⊗ No



Part 3C - Key dates

**Employee Share Scheme, Selective and Other Buy-Backs** 

3C.1 Anticipated date buy-back will occur

1/8/2022

Part 3D - Other Information

## 3D.1 Any other information the entity wishes to notify to ASX about the buy-back

In accordance with the terms of the Mayne Pharma Group Employee Loan plan, the Company is buying back and cancelling employee loan shares that have reached the grant expiry date and become forfeited shares as the performance conditions were not met or the share price was lower than the issue price of the shares. These shares were issued to employees in 2017.

## Part 5 - Final buy-back notification

For on-market buy-backs, a final buy-back notification must be submitted at least half an hour before the commencement of trading on the business day after the company buys back the maximum number of securities that it wanted or the company decides it will stop buying back securities.

For equal access buy-back schemes, a final buy-back notification must be submitted no later than five business days after the buy-back offer closing date.

For employee share scheme buybacks, selective buy-backs and other buy-backs, a final buy-back notification must be submitted by no later than five business days after the completion of the buy-back.

## 5.1 Total number of +securities bought back

25,025,249

## 5.2 Total consideration paid or payable for the securities

0.00000